Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

New authentication tool for counterfeit medicines

As Peter McAuley (The Pharmaceutical Journal 2014;293:180), Umakant Patel (The Pharmaceutical Journal 2014;293:151) and others have previously highlighted, there will be many issues in implementing and developing the largest IT project ever to hit these shores. However, we have to be mindful that the response by the EU is not a negotiation, it is a compulsory measure aimed at preventing falsified medicines entering the supply chain and into the hands of patients.

The aims of the EU directive and its associated delegated acts have merit because pharmaceutical crime is rising and the falsification of medicines accounted for the largest haul of counterfeit products recovered by EU customs officers last year. These were not only the usual, expensive lifestyle medicines but cheaper, high turnover generics. Because pharmacists are the healthcare professionals who interact with the most patients and whose focus is on the safe supply and use of medicines, the fight against counterfeit medicines has to be a priority for the profession and pharmacists must be committed to playing their part.

Understandably, most counterfeit medicines in Europe are acquired through illegal internet sources but, as counterfeiters become more sophisticated in their approach, the risk of a fake medicine entering the legal supply chain is real. Even if we believe the UK is counterfeit-proof, it is likely we will become more prone to attack by counterfeiters if we appear to be less rigorous than the rest of Europe.

Of course, the Royal Pharmaceutical Society (RPS) does not have a magic wand but it is central to key discussions. Through our hosted meetings and with stakeholder partners, we are lobbying for a national system that is not only implemented efficiently but is also cost-effective. We want an authentication tool that is robust, reliable and flexible enough to work in different sectors. It must be able to work alongside existing software on pharmacy systems, such as patient medication records, the electronic prescription service and the summary care record, in order to minimise bureaucracy and workforce pressure while adding professional value, improving service quality and enhancing patient care. We also want to protect generated data and avoid sacrificing the punctuality of access to medicines.

Finally, a key aim for the RPS is to raise public awareness of the threat counterfeit medicines pose and to ensure our members are not only aware but are engaging with us at every opportunity either through the RPS conference, our virtual pharmacy network or through The Pharmaceutical Journal before the implementation of the new authentication tool in 2018.


Sid Dajani, treasurer of the Royal Pharmaceutical Society, UK delegate of the Pharmaceutical Group of the European Union and Chairman of the Pan-Pharmacy Information Management and Technology Group of the RPS.

The views expressed here are his own and do not necessarily reflect those of the RPS, PGEU or the information management and technology group.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066347

Readers' comments (1)

  • It is very encouraging that a senior figure as Sid Dajani makes a strong defence of the 'Falsified Medicines Directive' (FMD) and its enactment EU-wide (over the coming four to six years) and furthermore asserts the capacity of the RPS to encourage appropriate refinements and adjustments to the implementation and practice of the Directive. Many observers might point out that while avoidance of entry of Counterfeit Product into the Legitimate Supply Chain is an entirely reasonable goal , efforts to secure high levels of Medicines Adherence must not be endangered in areas such as Phased Dispensing / Monitored Dosing Systems / supply of exact requested Quantities on Prescription eg Controlled Drugs. These aspects of our Practice must be jealously guarded or potentially ; less positive Health Outcomes may result. The Directive promises much in terms of heralding a new era in Pharmacy and may demonstrate the growing power of IT to secure our Supply Chain, however IT alone does not deliver excellence in Pharmaceutical Care. All Pharmacists , however , will be reassured that the RPS remains fully engaged in monitoring developments and relaying such to members. Such serious engagement is to be welcomed. Please maintain timely updates on developments in FMD and thanks for the opportunity to respond to Sid Dajani's contribution.
    Yours Sincerely, Tom Taaffe (Irish Pharmacist, MPSI Reg 6038), with many thanks and best wishes.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.